Physician profile
George Labban
NPI 1114925542
$520.47
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $47.23 · 2021: $13.93 · 2023: $86.82 · 2024: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202 · Education: $13.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.67 |
| Education | $13.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $150.48 | 2019-2024 | Lynparza |
| Novartis Pharmaceuticals Corporation | $45.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.44 | 2023 | Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $30.52 | 2019 | |
| Foundation Medicine, INC. | $30.46 | 2023 | |
| Eisai INC. | $26.36 | 2020 | |
| Genzyme Corporation | $23.61 | 2019 | |
| Janssen Biotech, INC. | $22.82 | 2019 | |
| Lilly USA, LLC | $22.39 | 2019 | |
| Tactile Systems Technology INC | $21.33 | 2019 | |
| Karyopharm Therapeutics INC. | $20.87 | 2020 | |
| Amgen INC. | $20.86 | 2019 | |
| Tesaro, INC. | $18.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Labban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.